Moclobemid Neuraxpharm (Moclobemide)

Moclobemide, the active ingredient in Moclobemid Neuraxpharm, is a monoamine oxidase inhibitor presented as an oral dosage form for oral use. It treats depressive disorders in adult patients.

GNH USA supplies Moclobemid Neuraxpharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moclobemide is a reversible monoamine oxidase A inhibitor used in the management of depressive disorders.

- Major depressive disorder: improves mood and functional outcomes. - Social anxiety disorder: reduces anxiety symptoms. - Persistent depressive disorder: alleviates chronic low mood.

Adverse reactions to Moclobemide vary from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Hypertensive crisis: sudden severe rise in blood pressure, especially with tyramine intake. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Serotonin syndrome: agitation, hyperthermia, neuromuscular abnormalities. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Careful monitoring and patient education are essential when prescribing Moclobemide.

- Assess hepatic function: obtain baseline liver enzymes before initiation. - Monitor blood pressure: watch for hypertensive episodes, particularly after consuming tyramine‑rich foods. - Avoid tyramine‑containing foods: maintain a low‑tyramine diet throughout therapy. - Review concomitant serotonergic agents: risk of serotonin syndrome. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Moclobemide interacts with several drug classes; some combinations must be avoided while others require close monitoring.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened serotonin toxicity. - Tricyclic antidepressants (TCAs): potential for hypertensive crisis. - Opioids such as meperidine: risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): may augment bleeding tendency. - Antihypertensive agents: possible additive hypotensive effect. - Cimetidine: may raise moclobemide plasma concentrations.